Cargando…
Proteomics in Melanoma Biomarker Discovery: Great Potential, Many Obstacles
The present clinical staging of melanoma stratifies patients into heterogeneous groups, resulting in the application of aggressive therapies to large populations, diluting impact and increasing toxicity. To move to a new era of therapeutic decisions based on highly specific tumor profiling, the disc...
Autores principales: | Sabel, Michael S., Liu, Yashu, Lubman, David M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195774/ https://www.ncbi.nlm.nih.gov/pubmed/22084682 http://dx.doi.org/10.1155/2011/181890 |
Ejemplares similares
-
Clinical Utility of Serum Autoantibodies Detected by Protein Microarray in Melanoma
por: Sabel, Michael S., et al.
Publicado: (2011) -
Differentiation therapy for glioblastoma – too many obstacles?
por: Carén, Helena, et al.
Publicado: (2015) -
Quantitative Proteomics for
Cardiac Biomarker Discovery
Using Isoproterenol-Treated Nonhuman Primates
por: Song, Benben, et al.
Publicado: (2014) -
Revisiting biomarker discovery by plasma proteomics
por: Geyer, Philipp E, et al.
Publicado: (2017) -
Liquid biomarkers in melanoma: detection and discovery
por: Lim, Su Yin, et al.
Publicado: (2018)